Who are Micardis's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Giapreza, Aralasin, Edarbi, Atacand, Avapro, Avapro.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/telmisartan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Micardis — Competitive Intelligence Brief

Micardis (TELMISARTAN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin 2 Receptor Blocker [EPC]. Area: Metabolic.

marketed Angiotensin 2 Receptor Blocker [EPC] Type-2 angiotensin II receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Micardis (TELMISARTAN) — Boehringer Ingelheim. Micardis works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Micardis TARGET	TELMISARTAN	Boehringer Ingelheim	marketed	Angiotensin 2 Receptor Blocker [EPC]	Type-2 angiotensin II receptor	1998-01-01
Giapreza	ANGIOTENSIN II	La Jolla Pharma	marketed	Vasoconstrictor [EPC]	Type-2 angiotensin II receptor, Type-1 angiotensin II receptor, Type-1 angiotensin II receptor	2017-01-01
Aralasin	SARALASIN	Procter And Gamble	marketed	saralasin	Type-2 angiotensin II receptor, Type-1 angiotensin II receptor, Angiotensin II receptor (AT-1) type-1	1982-01-01
Edarbi	AZILSARTAN MEDOXOMIL	Arbor Pharms Ireland	marketed	Angiotensin 2 Receptor Blocker	AT1 receptor	2011-01-01
Atacand	CANDESARTAN CILEXETIL	ANI Pharmaceuticals	marketed	Angiotensin 2 Receptor Blocker	Type-1 angiotensin II receptor	1998-01-01
Avapro	IRBESARTAN	Sanofi	marketed	Angiotensin 2 Receptor Blocker [EPC]	Type-1 angiotensin II receptor	1997-01-01
Avapro	IRBESARTAN HYDROCHLORIDE	Sanofi	marketed	Angiotensin 2 Receptor Blocker [EPC]	Type-1 angiotensin II receptor	1997-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-26 — Edarbi · 9066936 · US
2030-02-04 — Edarbi · 9169238 · US
2031-07-01 — Edarbi · 9387249 · US

Sponsor landscape (Angiotensin 2 Receptor Blocker [EPC] class)

Sanofi · 2 drugs in this class
Boehringer Ingelheim · 1 drug in this class
Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Micardis — Competitive Intelligence Brief. https://druglandscape.com/ci/telmisartan. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab